The trajectory of the erectile dysfunction drug presents a challenging picture for shareholders. While the initial launch generated massive gains, the lapse of its patent opened the door to generic alternatives, https://bookmarketmaven.com/story22511325/sildenafil-and-pharma-a-risky-opportunity